Isorhamnetin ameliorates hyperglycemia and dyslipidemia, improves plasma insulin, and preserves islet architecture in STZ-induced T1DM, while being associated with metabolite remodeling enriched for arachidonic- and glycerophospholipid-linked pathways. This evidence concerns the gene INS and metabolic syndrome.